Cumulative incidence of FVIII inhibitors in previously untreated or minimally treated patients with hemophilia A exposed only to single plasma-derived FVIII products (left panel open bars) or recombinant products (right panel closed bars). The data from these studies were the broad basis of the systematic reviews.^28,33,34  The names in the horizontal axis are those of the first authors of the corresponding articles, which are cited in the aforementioned systematic reviews.